Evidence map›Paper›PMID 29620157›Full record

ArticleInternational journal of oncology2018

Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer.

Dominik Buschmann, Ricardo González, Benedikt Kirchner, Claudia Mazzone, Michael W Pfaffl, Gustav Schelling, Ortrud Steinlein, Marlene Reithmair

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. The Role of Glucocorticoids in Breast Cancer Therapy.Current oncology (Toronto, Ont.) · 2022
    Review
  6. Review
  7. Genes · 2020
    Observational
  8. Caudatin Isolated fromBiomolecules · 2020
    Article
  9. Article
  10. FOXO1 and hsa-microRNA-204-5p affect the biologic behavior of MDA-MB-231 breast cancer cells.International journal of clinical and experimental pathology · 2020
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Dominik BuschmannInstitute of Human Genetics, University Hospital, LMU Munich, 80336 Munich, Germany.
Ricardo GonzálezInstitute of Human Genetics, University Hospital, LMU Munich, 80336 Munich, Germany.
Benedikt KirchnerDivision of Animal Physiology and Immunology, TUM School of Life Sciences Weihenstephan, Technical University of Munich, 85354 Freising, Germany.
Claudia MazzoneDepartment of Pharmacy and Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Michael W PfafflDivision of Animal Physiology and Immunology, TUM School of Life Sciences Weihenstephan, Technical University of Munich, 85354 Freising, Germany.
Gustav SchellingDepartment of Anesthesiology, University Hospital, LMU Munich, 81377 Munich, Germany.
Ortrud SteinleinInstitute of Human Genetics, University Hospital, LMU Munich, 80336 Munich, Germany.
Marlene ReithmairInstitute of Human Genetics, University Hospital, LMU Munich, 80336 Munich, Germany.
Ludwig-Maximilians-Universität München · DELMU Klinikum · DETechnical University of Munich · DESapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with limited options for clinical intervention. As with many solid tumors, TNBC is known to promote invasiveness and metastasis by secreting extracellular vesicles (EVs) capable of modulating the behaviour of recipient cells. Recent investigations have demonstrated that high expression levels of glucocorticoid receptor (GR) in TNBC are linked to therapy resistance, higher recurrence rates and increased mortality. In addition to activating protein-coding genes, GR is also involved in the expression of short non-coding RNAs including microRNAs (miRNAs or miRs). The molecular mechanisms responsible for the oncogenic effects of GR on TNBC have yet to be fully elucidated; however, emerging evidence suggests that miRNAs may play a pivotal role in tumorigenesis and metastasis. Thus, the aim of this study was to identify GR-regulated cellular and vesicular miRNAs that might contribute to the particularly oncogenic phenotype of TNBC with a high GR expression. We analyzed miRNA profiles of three TNBC cell lines using an in vitro model of GR overexpression. Next-generation sequencing revealed minor, cell line-specific changes in cellular miRNA expression, whereas vesicular miRNAs were not significantly regulated by GR. Additionally, the analysis of predicted miRNA targets failed to establish a causal link between GR-induced miRNA expression and oncogenic signaling. On the whole, given that GR influences miRNA profiles to only a small degree, other mechanisms are more likely to be responsible for the increased mortality of patients with TNBC with a high GR expression.

Indexed as

3' Untranslated RegionsCell CycleCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansMicroRNAsReceptors, GlucocorticoidSequence Analysis, DNASignal TransductionTriple Negative Breast Neoplasms3' Untranslated RegionsMicroRNAsReceptors, Glucocorticoid

Identifiers

PMID29620157
PMCPMC5919721
OpenAlexW2794814743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.